- Home
- ABTS vs GNPX Comparison
ABTS vs GNPX Comparison
Compare ABTS & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTS | GNPX |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 6.4M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ABTS | GNPX |
|---|---|---|
| Price | $2.78 | $1.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 830.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 76.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $0.14 |
| 52 Week High | $10.86 | $12.97 |
Technical Indicators
Market Signals| Indicator | ABTS | GNPX |
|---|---|---|
| Relative Strength Index (RSI) | 43.52 | 44.98 |
| Support Level | $2.13 | $1.90 |
| Resistance Level | $4.98 | $2.51 |
| Average True Range (ATR) | 0.60 | 0.21 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 22.57 | 30.26 |
Price Performance
Historical ComparisonAbout ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.